Skip to content
AAV Production

AAV Production

Optimised rAAV vector systems and production platforms for scalable viral vector manufacture

Recombinant adeno-associated viral vectors (rAAV) have emerged as a powerful tool for in vivo gene delivery owing to their unique characteristics, including a high safety profile and ability to drive long-term gene expression in humans. However, the ability to produce large quantities of functional rAAV particles in a scalable manufacturing system remains challenging. OXGENE has developed an optimised packaging plasmid system based on the reconfiguration of Rep-Cap coding sequences to increase the yield and quality of rAAV vectors produced. A clonal cGMP-compliant HEK293 suspension cell line has also been identified as the optimal rAAV production platform, enabling high-titre rAAV production for multiple serotypes and allowing rapid transfer to cGMP manufacture. Here, we provide an overview of the current rAAV production platform at OXGENE, focusing on the individual upstream and downstream unit operations, as well as analytical assay development for more accurate and complete characterisation of rAAV vectors.

Download the resource to read on...

We use cookies to give you the best experience of using this website. By continuing to use this site, you accept our use of cookies. Please read our Cookie Policy for more information.

Our single technology platform that fully connects our smart labs with our customer service proposition.


Connex revolutionises DNA design, optimization and assembly by ensuring the highest levels of quality control, efficiency and project management available for any client.

OXGENE has fully integrated all its smart labs and robotic production processes within a single technology platform that allows real-time project updates for our customers.